

Product Data Sheet

Product Name: Lesofavumab

Cat. No.: GC74569

Chemical Properties

Cas. No. 1807960-57-1

Formula

M.Wt

Solubility

Storage

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Lesofavumab

Background

Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody.

Lesofavumab (MHAB5553A) binds to a conserved epitope in the vestigial esterase domain of hemagglutinin (HA), a major immunodominant surface glycoprotein on influenza B viruses, and blocks HA-mediated membrane fusion in the endosome[1]. Lesofavumab (46B8) is able to neutralize

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

all eleven IBV strains tested that were associated with human infections spanning >70 years, with IC50 values ranging from 0.58 to 0.95 nM[2]. Lesofavumab (46B8; 0-100 ng/mL) blocks membrane fusion and induces antibody-dependent cellular cytotoxicity (ADCC) in vitro[2].

Lesofavumab (46B8; 15 mg/kg; i.v.; single dose) is able to protect mice against lethal challenge of the mutant influenza B virus[2].

References:

- [1]. Rao GK, et al. In Vivo Assessment of Antibody-Dependent Enhancement of Influenza B Infection. Toxicol Sci. 2019 Jun 1;169(2):409-421.
- [2]. Chai N, et al. A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. Nat Commun. 2017 Jan 19;8:14234.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA